Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting ...Middle East

CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. The data presented at ASH highlighted the latest safety and efficacy of CS5001 as a monotherapy for patients with advanced lymphomas. CS5001 is well tolerated in heavily...

Hence then, the article about encouraging efficacy and safety cstone presents latest clinical data on cs5001 for advanced lymphoma at the 66th ash annual meeting was published today ( Monday 09/12/2024 - 03:28 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting )

Also on site :

• The devil wears Old Navy? Inside Hollywood’s favorite movie marketing blitz
• India in talks with US and Iran on key port – Foreign Ministry
• How a Spanish startup pivoted to video AI and built a $230 million ARR business with no VC funding